The digital transformation of biopharmaceutical manufacturing has continued at a rapid pace as companies mine the rich sources of data available. The requirement for more people to maintain ‘physical distance’ during the coronavirus pandemic has helped to further fuel interest in digital solutions as companies sought to avoid delays and disruption to development, production and distribution. Innovations that enable data capture and review include predictive analytics, big data analytics, and building upon the digital plant. These forms of digital transformation offer mechanisms to revise its business model, to improve production processes, to design new drugs faster by using artificial intelligence (such as to screen compounds), and to increase responsiveness to customers. Furthermore, the volume of data processed by pharmaceutical firms shows no sign of slowing down. This means pharmaceutical companies must continue to act quickly in terms of building core internal digital capabilities and moving beyond their traditional IT functions to all areas of the business.
This content available exclusively for BPT Mebmers
Topics: Industry Trends